Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News JOHNSON & JOHNSON JNJ

Healthcare
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including... see more

Recent & Breaking News (NYSE:JNJ)

Johnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit

Business Wire July 10, 2023

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

GlobeNewswire June 12, 2023

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Business Wire June 6, 2023

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Business Wire May 10, 2023

Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Business Wire May 3, 2023

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Business Wire April 25, 2023

Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow

Business Wire April 24, 2023

Plaintiffs' Attorneys Representing Talc-Cancer Victims Form Ad Hoc Committee to Support J&J Settlement

PR Newswire April 21, 2023

Johnson & Johnson Reports Q1 2023 Results

Business Wire April 18, 2023

Johnson & Johnson Subsidiary LTL Management LLC ("LTL") Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims

Business Wire April 4, 2023

Talc Plaintiffs Will Press to Reopen Courthouse Doors

PR Newswire March 22, 2023

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Business Wire March 15, 2023

Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature

Business Wire March 15, 2023

Johnson & Johnson Announces Pricing of $7.75 Billion of Senior Notes Issued by Kenvue Inc.

Business Wire March 8, 2023

Johnson & Johnson Names Paula A. Johnson, President of Wellesley College, to its Board of Directors

Business Wire February 14, 2023

Johnson & Johnson to Participate in the Barclays Global HealthCare Conference

Business Wire February 14, 2023

Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D

Business Wire February 13, 2023

Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference

Business Wire February 2, 2023

Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits

PR Newswire January 31, 2023

Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits

PR Newswire January 30, 2023